Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat and Fulvestrant in HR+ Advanced Breast Cancer
NCT04999540Phase 2Unknown
- Sponsor
- Guangdong Women and Children Hospital
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in breast cancer, sponsored by Guangdong Women and Children Hospital. Primary endpoint: Progression Free Survival up to 3 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04999540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999540.